JUNIOR STRENGTH ADVIL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for JUNIOR STRENGTH ADVIL (JUNIOR STRENGTH ADVIL).
Non-selective cyclooxygenase (COX-1 and COX-2) inhibition, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
| Metabolism | Hepatic metabolism primarily via CYP2C9; also involves glucuronidation; major metabolites are hydroxylated and carboxylated forms. |
| Excretion | Primarily renal (90% as glucuronide conjugates and 10% unchanged); <5% biliary/fecal. |
| Half-life | 2-4 hours (terminal); prolonged in hepatic impairment and elderly. |
| Protein binding | 90-99% bound to albumin; concentration-dependent. |
| Volume of Distribution | 0.1-0.2 L/kg (low, consistent with high protein binding). |
| Bioavailability | Oral: 85-95% (ibuprofen susp/liquid); 80-100% (tablets/capsules). |
| Onset of Action | Oral: 15-30 minutes; peak effect 1-2 hours. |
| Duration of Action | 4-6 hours (analgesic/antipyretic); 6-8 hours (anti-inflammatory at higher doses). |
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for OTC use.
| Dosage form | TABLET, CHEWABLE |
| Renal impairment | eGFR 30-60 mL/min: reduce dose by 50% or extend interval to q8-12h; eGFR <30 mL/min: avoid use. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: avoid use. |
| Pediatric use | 5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day (or 1200 mg/day) for children ≥6 months. |
| Geriatric use | Start at lowest effective dose (200 mg q6-8h); maximum 1200 mg/day; monitor renal function and GI bleeding risk. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for JUNIOR STRENGTH ADVIL (JUNIOR STRENGTH ADVIL).
| Breastfeeding | Ibuprofen is excreted into breast milk in low concentrations (M/P ratio approximately 0.01). Not expected to cause adverse effects in infants with short-term use at recommended doses. Avoid in nursing mothers breastfeeding preterm or low-birth-weight infants. |
| Teratogenic Risk | Avoid during third trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal dysfunction. First and second trimester use only if clearly needed; limited human data suggest low risk of major malformations but increased risk of miscarriage and cardiac defects. |
■ FDA Black Box Warning
No FDA boxed warning for JUNIOR STRENGTH ADVIL (ibuprofen). However, NSAIDs in general carry a boxed warning for cardiovascular thrombotic events and gastrointestinal bleeding.
| Common Effects | Nausea Headache Flatulence Diarrhea |
| Serious Effects |
["Hypersensitivity to ibuprofen or any component of the formulation","Asthma, urticaria, or allergic-type reactions after aspirin or other NSAID use","Treatment of perioperative pain in coronary artery bypass graft (CABG) surgery","Use in children with chickenpox (due to increased risk of severe skin reactions)"]
| Precautions | ["Cardiovascular risk: Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke","Gastrointestinal risk: Increased risk of GI bleeding, ulceration, and perforation","Renal effects: May cause renal impairment, especially in patients with pre-existing renal disease","Hypersensitivity reactions: Anaphylaxis, bronchospasm","Fluid retention and edema","Avoid use with other NSAIDs or in late pregnancy (risk of premature closure of ductus arteriosus)"] |
Loading safety data…
| Fetal Monitoring | Monitor fetal heart rate, amniotic fluid index, and ductus arteriosus patency with ultrasound if used in third trimester. Assess maternal renal function, bleeding time, and platelet count with prolonged therapy. |
| Fertility Effects | Reversible inhibition of ovulation due to inhibition of prostaglandin synthesis. Use may delay or impair fertility in women attempting conception; discontinue use if difficulty conceiving. |